Company Description
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.
The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.
Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally.
The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 2 |
CEO | Jason V. Matuszewski |
Contact Details
Address: 2836 Center Port Circle Pompano Beach, Florida 33604 United States | |
Phone | 954-380-8342 |
Website | biostemtechnologies.com |
Stock Details
Ticker Symbol | BSEM |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001658678 |
ISIN Number | US0906842002 |
Employer ID | 27-0400416 |
Key Executives
Name | Position |
---|---|
Jason Matuszewski | Chief Executive Officer, President, Director and Secretary |
Michael Fortunato CPA | Chief Financial Officer |
Andrew Vanvurst | Chief Operating Officer and Director |
Dr. David M. Woynarowski | Chief Medical Officer |
Larry Jones | Chief Revenue Officer |
Dr. Irmgard Huber M.D. | International Medical Advisor and Interim Chief Medical Officer |
Shawn F. McCarrey | Chief Commercial Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 4, 2023 | D | Notice of Exempt Offering of Securities |
May 25, 2021 | D | Notice of Exempt Offering of Securities |
Aug 16, 2016 | D | Notice of Exempt Offering of Securities |
Feb 1, 2016 | D | Notice of Exempt Offering of Securities |